VEGFA and age-related macular degeneration: EPC-dependent angiogenesis appears to be a valuable treatment target for neovascular AMD, as the anti-VEGF drug ranibizumab significantly reduces the high levels of circulating EPCs that are involved in AMD angiogenesis [21].